Immunotherapy in bladder cancer

Current Molecular Pharmacology

Volumn 9, Issue 3, 2016, Pages 242-251

  Vasekar, Monali ^a   Degraff, David ^b   Joshi, Monika ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder cancer; Cytokines; Immunotherapy; Interferon; PD L1 inhibitors; PD1 inhibitors

Indexed keywords

BCG VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; PROGRAMMED DEATH 1 RECEPTOR;

BLADDER CANCER; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VACCINATION; IMMUNOLOGY; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; URINARY BLADDER NEOPLASMS;

EID: 84989233217     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467208666150716120945     Document Type: Review

References (66)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin., 2015, 65(1), 5-29.
2. Kemp, T.J.; Ludwig, A.T.; Earel, J.K.; Moore, J.M.; Vanoosten, R.L.; Moses, B.; Leidal, K.; Nauseef, W.M.; Griffith, T.S., Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood, 2005, 106(10), 3474-3482.
3. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 2011, 331(6024), 1565-1570.
4. Kamat, A.M.; Flaig, T.W.; Grossman, H.B.; Konety, B.; Lamm, D.; O’Donnell, M.A.; Uchio, E.; Efstathiou, J.A.; Taylor, J.A. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat. Rev. Urol., 2015, 12(4), 225-235.
5. Morales, A.; Eidinger, D.; Bruce, A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 1976, 116(2), 180-183.
6. Han, R.F.; Pan, J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology, 2006, 67(6), 1216-1223.
7. Shelley, M.D.; Kynaston, H.; Court, J.; Wilt, T.J.; Coles, B.; Burgon, K.; Mason, M.D. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int., 2001, 88(3), 209-216.
8. Lamm, D.L.; Crissmann, J.; Blumenstein, B.; Crawford, E.D.; Montie, J.; Scardino, P.; Grossman, H.B.; Stanisic, T.; Smith, J.; Sullivan, J. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study. Prog. Clin. Biol. Res., 1989, 310, 263-270.
9. Lamm, D.L.; Blumenstein, B.A.; Crawford, E.D.; Montie, J.E.; Scardino, P.; Grossman, H.B.; Stanisic, T.H.; Smith, J.A.; Sullivan, J.; Sarosdy, M.F. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitionalcell carcinoma of the bladder. N. Engl. J. Med., 1991, 325(17), 1205-1209.
10. Lamm, D.L.; Blumenstein, B.A.; David Crawford, E.; Crissman, J.D.; Lowe, B.A.; Smith, J.A.; Sarosdy, M.F.; Schellhammer, P.F.; Sagalowsky, A.I.; Messing, E.M.; Loehrer, P.; Barton Grossman, H. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol. Oncol., 1995, 1(3), 119-126.
11. Bohle, A.; Jocham, D.; Bock, P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol., 2003, 169(1), 90-95.
12. O’Donnell, M.A.; Boehle, A., Treatment options for BCG failures. World J. Urol., 2006, 24(5), 481-487.
13. Ratliff, T.L.; Kavoussi, L.R.; Catalona, W.J., Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol., 1988, 139(2), 410-414.
14. Wishahi, M.M.; Ismail, I.M.; el-Sherbini, M. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis. Br. J. Urol., 1994, 73, (6), 649-654.
15. Lamm, D.L.; van der Meijden, P.M.; Morales, A.; Brosman, S.A.; Catalona, W.J.; Herr, H.W.; Soloway, M.S.; Steg, A.; Debruyne, F.M., Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol., 1992, 147(3), 596-600.
16. Lamm, D.L. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur. Urol., 1992, 21(Suppl. 2), 12-16.
17. Sylvester, R.J.; van der, M.A.; Lamm, D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol., 2002, 168(5), 1964-1970.
18. Rentsch, C.A.; Birkhauser, F.D.; Biot, C.; Gsponer, J.R.; Bisiaux, A.; Wetterauer, C.; Lagranderie, M.; Marchal, G.; Orgeur, M.; Bouchier, C.; Bachmann, A.; Ingersoll, M.A.; Brosch, R.; Albert, M.L.; Thalmann, G.N. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur. Urol., 2014, 66(4), 677-688.
19. Losa, A.; Hurle, R.; Lembo, A., Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J. Urol., 2000, 163(1), 68-71, discussion 71-62.
20. Glashan, R.W. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J. Urol., 1990, 144(3), 658-661.
21. Portillo, J.; Martin, B.; Hernandez, R.; Correas, M.; Gutierrez, J.; Del Valle, J.; Roca, A.; Vega, A.; Villanueva, A.; Gutierrez, R. Results at 43 months’ follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology, 1997, 49(2), 187-190.
22. O’Donnell, M.A.; Krohn, J.; DeWolf, W.C., Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J. Urol., 2001, 166(4), 1300-1304, discussion 1304-1305.
23. Joudi, F.N.; Smith, B.J.; O’Donnell, M.A.; Group, N.B.-I.P.I. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol., 2006, 24(4), 344-348.
24. Nepple, K.G.; Lightfoot, A.J.; Rosevear, H.M.; O’Donnell, M.A.; Lamm, D.L.; Group, B.C.G.O.S., Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J. Urol., 2010, 184(5), 1915-1919.
25. Ojea, A.; Nogueira, J.L.; Solsona, E.; Flores, N.; Gomez, J.M.; Molina, J.R.; Chantada, V.; Camacho, J.E.; Pineiro, L.M.; Rodriguez, R.H.; Isorna, S.; Blas, M.; Martinez-Pineiro, J.A.; Madero, R., A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur. Urol., 2007, 52(5), 1398-1406.
26. Lamm, D.L.; Blumenstein, B.A.; Crissman, J.D.; Montie, J.E.; Gottesman, J.E.; Lowe, B.A.; Sarosdy, M.F.; Bohl, R.D.; Grossman, H.B.; Beck, T.M.; Leimert, J.T.; Crawford, E.D. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol., 2000, 163(4), 1124-1129.
27. Ehdaie, B.; Sylvester, R.; Herr, H.W. Maintenance bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur. Urol., 2013, 64(4), 579-585.
28. Pfister, C.; Kerkeni, W.; Rigaud, J.; Le Gal, S.; Saint, F.; Colombel, M.; Guy, L.; Wallerand, H.; Irani, J.; Soulie, M., Efficacy and tolerance of one-third full dose bacillus Calmette-Guerin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int. J. Urol., 2015, 22(1), 53-60.
29. Oddens, J.; Brausi, M.; Sylvester, R.; Bono, A.; van de Beek, C.; van Andel, G.; Gontero, P.; Hoeltl, W.; Turkeri, L.; Marreaud, S.; Collette, S.; Oosterlinck, W., Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol., 2013, 63(3), 462-472.
30. Jonasch, E.; Haluska, F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. The Oncologist, 2001, 6(1), 34-55.
31. Arnold, J.; de Boer, E.C.; O’Donnell, M.A.; Böhle, A.; Brandau, S., Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J. Immunother., 2004, 27(2), 116-123.
32. Haaff, E.O.; Catalona, W.J.; Ratliff, T.L., Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. The Journal of urology, 1986, 136(4), 970-974.
33. O’Donnell, M.A.; Luo, Y.; Chen, X.; Szilvasi, A.; Hunter, S.E.; Clinton, S.K., Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. J. Immunol., 1999, 163(8), 4246-4252.
34. Nadler, R.; Luo, Y.; Zhao, W.; Ritchey, J.K.; Austin, J.C.; Cohen, M.B.; O’Donnell, M.A.; Ratliff, T.L., Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin. Exp. Immunol., 2003, 131(2), 206-216.
35. Morgan, D.A.; Ruscetti, F.W.; Gallo, R., Selective in vitro growth of T lymphocytes from normal human bone marrows. Science, 1976, 193(4257), 1007-1008.
36. Ruscetti, F.W.; Morgan, D.A.; Gallo, R.C. Functional and morphologic characterization of human T cells continuously grown in vitro. J. Immunol., 1977, 119, (1), 131-138.
37. Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Chang, A.E.; Avis, F.P.; Leitman, S.; Linehan, W.M.; Robertson, C.N.; Lee, R.E.; Rubin, J.T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 1987, 316(15), 889-897.
38. Askeland, E.J.; Newton, M.R.; O’Donnell, M.A.; Luo, Y., Bladder Cancer Immunotherapy: BCG and Beyond. Adv. Urol., 2012, 2012, 181987.
39. Tubaro, A.; Velotti, F.; Stoppacciaro, A.; Santoni, A.; Vicentini, C.; Bossola, P.C.; Galassi, P.; Pettinato, A.; Morrone, S.; Napolitano, T., Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study. Cancer, 1991, 68(1), 56-61.
40. Den Otter, W.; Dobrowolski, Z.; Bugajski, A.; Papla, B.; Van Der Meijden, A.P.; Koten, J.W.; Boon, T.A.; Siedlar, M.; Zembala, M., Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J. Urol., 1998, 159(4), 1183-1186.
41. O’Donnell, M.A.; Aldovini, A.; Duda, R.B.; Yang, H.; Szilvasi, A.; Young, R.A.; DeWolf, W.C. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect. Immun., 1994, 62(6), 2508-2514.
42. Yamada, H.; Matsumoto, S.; Matsumoto, T.; Yamada, T.; Yamashita, U. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J. Urol., 2000, 164(2), 526-531.
43. Manetti, R.; Parronchi, P.; Giudizi, M.G.; Piccinni, M.P.; Maggi, E.; Trinchieri, G.; Romagnani, S., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)- specific immune responses and inhibits the development of IL-4- producing Th cells. J. Exp. Med., 1993, 177(4), 1199-1204.
44. Atkins, M.B.; Robertson, M.J.; Gordon, M.; Lotze, M.T.; DeCoste, M.; DuBois, J.S.; Ritz, J.; Sandler, A.B.; Edington, H.D.; Garzone, P.D.; Mier, J.W.; Canning, C.M.; Battiato, L.; Tahara, H.; Sherman, M.L., Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 1997, 3(3), 409-417.
45. Gollob, J.A.; Veenstra, K.G.; Parker, R.A.; Mier, J.W.; McDermott, D.F.; Clancy, D.; Tutin, L.; Koon, H.; Atkins, M.B., Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol., 2003, 21(13), 2564-2573.
46. Weiss, G.R.; O’Donnell, M.A.; Loughlin, K.; Zonno, K.; Laliberte, R.J.; Sherman, M.L. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J. Immunother., 2003, 26(4), 343-348.
47. Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; M D, J.W.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; Davidson, N.; Richards, J.; Maio, M.; Hauschild, A.; Miller, W.H.; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T.T.; Humphrey, R.; Hoos, A.; Wolchok, J.D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med., 2011, 364(26), 2517-2526.
48. Pentcheva-Hoang, T.; Corse, E.; Allison, J.P. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev., 2009, 229(1), 67-87.
49. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366(26), 2455-2465.
50. Kandoth, C.; McLellan, M.D.; Vandin, F.; Ye, K.; Niu, B.; Lu, C.; Xie, M.; Zhang, Q.; McMichael, J.F.; Wyczalkowski, M.A.; Leiserson, M.D.; Miller, C.A.; Welch, J.S.; Walter, M.J.; Wendl, M.C.; Ley, T.J.; Wilson, R.K.; Raphael, B.J.; Ding, L. Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502(7471), 333-339.
51. Chen, D.S.; Mellman, I. Oncology meets immunology: the cancerimmunity cycle. Immunity, 2013, 39(1), 1-10.
52. Powles, T.; Eder, J.P.; Fine, G.D.; Braiteh, F.S.; Loriot, Y.; Cruz, C.; Bellmunt, J.; Burris, H.A.; Petrylak, D.P.; Teng, S.L.; Shen, X.; Boyd, Z.; Hegde, P.S.; Chen, D.S.; Vogelzang, N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515(7528), 558-562.
53. Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; Kohrt, H.E.; Horn, L.; Lawrence, D.P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P.S.; Mellman, I.; Chen, D.S.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528), 563-567.
54. Gallagher, D.J.; Milowsky, M.I.; Gerst, S.R.; Ishill, N.; Riches, J.; Regazzi, A.; Boyle, M.G.; Trout, A.; Flaherty, A.M.; Bajorin, D.F. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol., 2010, 28(8), 1373-1379.
55. Necchi, A.; Mariani, L.; Zaffaroni, N.; Schwartz, L.H.; Giannatempo, P.; Crippa, F.; Morosi, C.; Lanocita, R.; Sava, T.; Ortega, C.; Messina, C.; Sacco, C.; Pennati, M.; Daidone, M.G.; Nicolai, N.; De Braud, F.; Gianni, A.M.; Salvioni, R. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol., 2012, 13(8), 810-816.
56. Seront, E.; Rottey, S.; Sautois, B.; Kerger, J.; D’Hondt, L.A.; Verschaeve, V.; Canon, J.L.; Dopchie, C.; Vandenbulcke, J.M.; Whenham, N.; Goeminne, J.C.; Clausse, M.; Verhoeven, D.; Glorieux, P.; Branders, S.; Dupont, P.; Schoonjans, J.; Feron, O.; Machiels, J.P., Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann. Oncol., 2012, 23(10), 2663-2670.
57. Bellmunt, J.; Théodore, C.; Demkov, T.; Komyakov, B.; Sengelov, L.; Daugaard, G.; Caty, A.; Carles, J.; Jagiello-Gruszfeld, A.; Karyakin, O.; Delgado, F.M.; Hurteloup, P.; Winquist, E.; Morsli, N.; Salhi, Y.; Culine, S.; von der Maase, H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol., 2009, 27(27), 4454-4461.
58. Choueiri, T.K.; Ross, R.W.; Jacobus, S.; Vaishampayan, U.; Yu, E.Y.; Quinn, D.I.; Hahn, N.M.; Hutson, T.E.; Sonpavde, G.; Morrissey, S.C.; Buckle, G.C.; Kim, W.Y.; Petrylak, D.P.; Ryan, C.W.; Eisenberger, M.A.; Mortazavi, A.; Bubley, G.J.; Taplin, M.E.; Rosenberg, J.E.; Kantoff, P.W. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum- pretreated metastatic urothelial cancer. J. Clin. Oncol., 2012, 30(5), 507-512.
59. Daniel Peter Petrylak; Thomas Powles; Joaquim Bellmunt; Fadi S. Braiteh; Yohann Loriot; Cristina Cruz Zambrano; Howard A. Burris; Joseph W. Kim; Siew-leng Melinda Teng; Jean-Marie Bruey; Priti Hegde; Oyewale O. Abidoye; Vogelzang, N.J. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). J. Clin. Oncol., 33, 2015 (suppl; abstr 4501).
60. Kim, J.W.; Bellmunt, J.; Powles, T.; Loriot, Y.; Vogelzang, N.J.; Zambrano, C.C.; Burris, H.A.; Teng, S-L.M.; Shen, X.; Bruey, JM.; Boyd, Z.; Hegde, P.S.; Petrylak, D.P. Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. J. Clin. Oncol., 2015, 33(suppl 7; abstr 297).
61. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366(26), 2443-2454.
62. Plimack, E.R.; Gupta, S.; Bellmunt, J.; Berger, R.; Montgomery, B.; Gonzalez, E.J.; Pulini, J.; Dolled-Filhart, M.; Emancipator, K.; Pathiraja, K.; Gause, C.; Perini, R.; Cheng, J.D.; O’donnell, P.H., A phase IB study of pembrolizumab (Pembro; MK3475) in patients (Pts) with advanced urothelial tract cancer. LBA23 ESMO 2014.
63. Plimack, E.R.; Bellmunt, J.; Gupta, S.; Berger, R.; Montgomery, R.B.; Heath, K.; Juco, J.; Emancipator, K.; Pathiraja, K.; Lunceford, J.K.; Perini, R.F.; O’Donnell, P.H. Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. J. Clin. Oncol., 2015 33(suppl; abstr 4502).
64. Grosso, J.F.; Jure-Kunkel, M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun., 2013, 13, 5.
65. Carthon, B.C.; Wolchok, J.D.; Yuan, J.; Kamat, A.; Ng Tang, D.S.; Sun, J.; Ku, G.; Troncoso, P.; Logothetis, C.J.; Allison, J.P.; Sharma, P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res., 2010, 16(10), 2861-2871.
66. Tang, C.; Wang, X.; Soh, H.; Seyedin, S.; Cortez, M.A.; Krishnan, S.; Massarelli, E.; Hong, D.; Naing, A.; Diab, A.; Gomez, D.; Ye, H.; Heymach, J.; Komaki, R.; Allison, J.P.; Sharma, P.; Welsh, J.W. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol. Res., 2014, 2(9), 831-838.